Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002408254 | SCV002721973 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-07-10 | criteria provided, single submitter | clinical testing | The c.19_22dupAGCA variant, located in coding exon 1 of the CDKN2A gene, results from a duplication of AGCA at nucleotide position 19, causing a translational frameshift with a predicted alternate stop codon (p.S8Kfs*8). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV003746642 | SCV004458325 | pathogenic | Familial melanoma | 2023-04-19 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1782299). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with CDKN2A (p16INK4a)-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser8Lysfs*8) in the CDKN2A (p16INK4a) gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CDKN2A (p16INK4a) are known to be pathogenic (PMID: 15146471, 16905682). |